biotech
biotech on Beyond Market Intelligence: a running collection of 2 stories we have gathered and hand-picked because they are worth your time. Every post here touches on biotech in some way — the news, the analysis, the deep dives, and the occasional surprise find. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work with data. New stories are added to this page as we find them, so check back if you want to keep up with what is happening around biotech, or subscribe to the RSS feed to get them as soon as they are published. Browse the collection below, or head back to the homepage to see everything Beyond Market Intelligence is covering right now.
“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
Vijay Pande, formerly of a16z’s $4 billion biotech practice and now leading the AI-native VZVC, argues that biology is undergoing a critical shift from discovery to engineering. Pande emphasizes a strategic shift away from numerous, smaller bets, stating, "We’re not doing 30 bets a year.” He highlights the persistent challenges of clinical trial costs and champions the power of open, shared datasets as the key to unlocking AI’s transformative potential in medicine.
Science Corporation’s vision-restoring chip wins EU approval
Science Corporation has achieved a significant milestone: its vision-restoring chip has secured EU approval, marking a pivotal moment for potential treatments. CEO Max Hodak emphasized the need for sustained commercial success, stating, "The thing that the space needs is a company making $100 million a year of revenue." This regulatory clearance positions Science Corporation to explore broader applications and impact.